Loading...
Uploaded by RigelPharmaceuticals on Nov 2, 2011
Rigel's oral Janus Kinase 3 (JAK3) inhibitor program is focused on organ transplant rejection. JAK3 is critical to immune system activation and is an attractive target because its expression is limited to key cells in the immune system.
Science & Technology
Standard YouTube License
Very good explained!
aramfare 2 months ago
Load more suggestions
Very good explained!
aramfare 2 months ago